ATARA Biotherapeutics (ATRA) Tops Q1 EPS by 6c

ATARA Biotherapeutics (NASDAQ: ATRA) reported Q1 EPS of ($0.86), $0.06 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $3.55 million versus the consensus estimate of $1.6 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Coty stock tumbles as lack of visibility, RBC downgrade overshadow Q4 beat
• Twin Disc (TWIN) Tops Q4 EPS by 16c